Clinical trial
Olmesartan as an add-on to Amlodipine in Hypertension
NCT00220233 · Sankyo Pharma Gmbh, Industry · Completed
Key facts
| NCT number | NCT00220233 |
|---|---|
| Title | Olmesartan as an add-on to Amlodipine in Hypertension |
| Official title | Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone |
| Lead sponsor | Sankyo Pharma Gmbh, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug |
| Interventions | olmesartan medoxomil, amlodipine, hydrochlorothiazide |
| Enrollment | 632 |
| Start date | Apr 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 24, 2018 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: